Core Viewpoint - Magnesium Health is preparing for its second IPO attempt on the Hong Kong Stock Exchange, aiming to raise funds as a leading multi-payment platform in the pharmaceutical sector, with significant revenue growth and improving financial metrics [1][8]. Company Overview - Magnesium Health is the largest multi-payment platform in China for pharmaceuticals, ranking first in both the innovative smart drug solutions market and the innovative health insurance solutions market based on partnerships with pharmaceutical companies and processed health insurance policies [1][3]. Financial Performance - For the fiscal year ending December 31, 2024, the company reported revenues of approximately RMB 20.35 billion, a 60% year-on-year increase, with a net loss of RMB 0.76 billion, narrowing by 70% [1][8]. - In the first ten months of 2025, revenues reached RMB 18.73 billion, a 30% year-on-year increase, but the net loss expanded to RMB 3.89 billion, a 366.93% increase in losses compared to the previous year [1][8]. - The gross profit margin for 2024 was 35.83%, while the gross profit for the first ten months of 2025 was RMB 6.01 billion, reflecting a 10.47% year-on-year increase [6][8]. Market Position - The company has served approximately 2 million patients, with a total medical expenditure of RMB 50.2 billion, and has partnerships with over 100 insurance companies, including all of China's top 20 insurers by premium income for 2024 [5][10]. - The innovative smart drug solutions market in China is projected to grow from RMB 521 billion in 2019 to RMB 910 billion by 2024, with a compound annual growth rate of 11.8% [10]. Product and Service Offerings - Magnesium Health has developed two major industry solutions: smart drug solutions and smart insurance solutions, aimed at providing comprehensive commercialization plans for pharmaceutical companies and end-to-end solutions for insurance companies [3][8]. - The company also offers consumer-facing services, including BluePass and a DTC pharmacy platform, designed to enhance patient experience and outcomes [3][8]. Competitive Landscape - Magnesium Health's market performance highlights its leading competitive position, with a significant number of partnerships and processed health insurance policies compared to competitors [13][15]. - The company has undergone multiple rounds of financing, raising over RMB 31.8 billion, with a post-money valuation of approximately RMB 116.8 billion following its latest financing round in December 2022 [19].

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或因依賴該等內容而引致的 任何損失承擔任何責任。 Shanghai MediTrust Health Technology Group Co., Ltd.* 上海鎂信健康科技集團股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，當中所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣 下知悉、接納並向本公司、其聯席保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，準投資者務請僅依據經香港公司註冊處處長登記的本公司 招股章程作出投資決定；招股章程的文本將於發售期內向公眾刊發。 * 僅供識別 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本文件中 的資料作出任何 ...